HYPR · Hyperfine, Inc.
$0.83
+0.03 (+3.40%)
At close · Sep 3
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company’s existing capital resources, including the net proceeds from the recent offerings described below, are expected to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these condensed consolidated financial statements. Unless and until the Company is able to generate a sufficient amount of revenue and generate positive operating cash flows, the Company expects to finance future cash needs through public and/or private offerings of equity securities and/or debt financings. If the Company is not able to obtain additional financing and/or substantially increase revenue from sales, in the longer term, it could result in a substantial doubt about the Company's ability to continue as a going concern. Management believes the net proceeds from the recent offerings, described under Note 9 – “Debt” and Note 10 – “Stockholders’ Equity”, and the Company’s anticipated revenue, provide sufficient liquidity to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$86.66M
Shares
106.05M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$13.56M
+5.2%
FY2025
Net Income
-$35.57M
+12.6%
FY2025
Gross Margin
49.79%
+4.1pp
FY2025
Operating Margin
-273.43%
+61.9pp
FY2025
Diluted EPS
-$0.43
+23.2%
FY2025
Operating Cash Flow
-$27.95M
+27.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $16.54M | $13.56M | $12.89M | $11.03M | $6.81MG | $1.5M | $294K | |
| $8.04M | $6.81M | $7M | $6.28M | $5.91M | $2.66M | $771K | |
| $8.5M | $6.75M | $5.89M | $4.76M | $907K | -$1.17M | -$477K | |
| — | 49.79% | 45.7% | 43.12% | 13.31% | -78.01% | -162.24% | |
| $15.58M | $17.45M | $22.5M | $22.49M | $28.16M | $25.84M | $14.59M | |
| $10.31M | $10.13M | $9.12M | $10.1M | $14.22M | $10.36M | $2.5M | |
| $16.22M | $16.25M | $17.49M | $20.28M | $32.41M | $27.5M | $5.92M | |
| — | — | — | — | $1.02M | $726K | $289K | |
| $42.12M | $43.84M | $49.12M | $52.87M | $74.78M | $63.7M | $23.01M | |
| -$33.62M | -$37.09M | -$43.22M | -$48.12M | -$73.87M | -$64.87M | -$23.49M | |
| — | -273.43% | -335.33% | -436.14% | -1084.15% | -4336.1% | -7990.14% | |
| — | — | — | — | -$72.86M | -$64.14M | -$23.2M | |
| $993K | $1.02M | $2.49M | $3.84M | $761K | $18K | $70K | |
| $37K | -$337K | $12K | $35K | -$51K | -$1000 | -$6000 | |
| -$34.85M | -$35.57M | -$40.72M | -$44.24M | -$73.16M | -$64.85M | -$23.43M | |
| $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$34.85M | -$35.57M | -$40.72M | -$44.24M | -$44.24M | -$64.85M | -$23.43M | |
| — | -262.29% | -315.9% | -401% | -649.22% | -4334.96% | -7968.37% | |
| USD/shares | -$0.37 | -$0.43 | -$0.56 | -$0.62 | -$1.04 | -$17.57 | — |
| USD/shares | -$0.37 | -$0.43 | -$0.56 | -$0.62 | -$1.04 | -$17.57 | — |
| shares | — | 81.8M | 72.41M | 71.32M | 70.45M | 3.69M | 1.52M |
| shares | — | 81.8M | 72.41M | 71.32M | 70.45M | 3.69M | 1.52M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 41 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.41×
Peer median 1.56×
EV/EBIT
—
Peer median 14.21×
P/E (TTM)
—
Peer median 27.52×
Peer medians compare against the 75 similar-size Medical Devices companies (of 145 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Non Us | $3,152,000 | $6,394,000 | $4,362,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $11,398,000 | $10,450,000 | $8,746,000 | $5,246,000 | $715,000 | $200,000 |
| Service | $2,165,000 | $2,440,000 | $2,286,000 | $1,568,000 | $781,000 | $94,000 |
Key facts
CIK
1833769
CUSIP
44916K106
13F (30d)
67 filings
67 filers
Visit website
Investor relations